Lifetime of transplanted kidneys can be prolonged

September 10, 2013
Lifetime of transplanted kidneys can be prolonged

The drug Belatacept, which the Medical University of Vienna – represented by Ferdinand Mühlbacher, Head of the University Department of Surgery and the immunologist Thomas Wekerle – was greatly involved in the development of, has been approved for almost two years now. Belatacept is a co-stimulation blocker that suppresses the immune response in kidney transplants and has few side effects. "Plus there are indications that the drug can also help significantly prolong the lifetime of the transplanted organ," says Wekerle.

There is no final data available yet on the lifetime of transplanted kidneys and subsequent therapy with Belatacept, however estimates predict a prolongation of several years compared to the current treatment regime based on the conventional immunosuppressants known as calcineurin inhibitors.

The new therapy also has another advantage compared to calcineurin inhibitors: it has no non-specific side effects. For almost 30 years, have been used for the lifelong suppression of adverse reactions of the immune system to . These drugs have been associated with possible adverse side effects such as , disturbances of fat metabolism or diabetes.

At the same time, Belatacept is much easier to administer as a medication: every four weeks, the patient is given an infusion that takes around 30 minutes. With , the patients have to take tablets every day. At the present time, Belatacept treatment is not funded by health insurance funds. The costs for patients treated with this drug at the Vienna General Hospital / MedUni Vienna, however, are paid for by the hospital and/or university. Says Wekerle: "Of course, in an ideal world the costs would be borne by the social security funds."

A vision of the future: bone marrow transplant instead of medication

Current research being carried out by MedUni Vienna scientists, however, is already going one step further. In future, will no longer be required at all, being replaced by a from the donor. This prevents any defence reaction against the "foreign" organ.

This is however still associated with adverse side effects: recipients must first be irradiated and be given synthetic substances (cytostatics) to inhibit cell growth or cell division. This treatment is associated with nausea and a reduction in white and/or red blood cells. "If we are able to reduce this toxicity or eliminate it altogether, it would be revolutionary," says Wekerle. "If we are able to get the foreign bone marrow to graft, the recipient will not recognise the donor organ as foreign. There will be no immune response. Instead, the patient tolerates it." Initial pilot studies have shown that this method promises success.

Explore further: Bone marrow transplantation assists in acceptance of donated organs

Related Stories

Bone marrow transplantation assists in acceptance of donated organs

April 3, 2012
In an organ transplant the recipient protects himself with an immune reaction against the alien organ. This reaction is counteracted long-term with the use of immunosuppressants. In future this medication might no longer ...

Belatacept after a kidney transplant: Minor added benefit for certain patients

November 9, 2012
Belatacept (trade name Nulojix) has been approved since June 2011 to prevent a rejection reaction of the body to the donor organ (transplant) in adults who have received a kidney transplant. The Institute for Quality and ...

Taking rejection out of organ transplant operations

July 31, 2013
Organ transplant operations save lives. But for recipients, treatment does not end with an operation - they must take medication for the rest of their lives.

Dendritic cell therapy improves kidney transplant survival, study says

June 28, 2013
(Medical Xpress)—A single systemic dose of special immune cells prevented rejection for almost four months in a preclinical animal model of kidney transplantation, according to experts at the University of Pittsburgh School ...

Promising stem cell therapy for leukemia patients

April 2, 2013
Leukemia patients receive a bone marrow transplant, which allows them to build a "new" immune system. However, this immune system not only attacks cancer cells but healthy tissue too. Special antibodies will be used to protect ...

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.